Investor Presentaiton

Investor presentation First three months of 2017 Slide 104 Novo Nordisk has delivered sustained growth throughout the last decade 30% Sales growth in local currencies 2007-2016 Sales growth Operating profit growth in local currencies Average growth 30% 2007-2016 Operating profit growth Average growth 20% 10% 0% lin 2007 changing diabetes 20% 11% 10% 0% 2016 2007 Note: Numbers for 2007 and 2008 are adjusted for the impact of the discontinuation of pulmonary insulin projects; Numbers for 2015 and 2016 are adjusted for the non- recurring income related to the partial divestment of NNIT with the dotted component representing this income; average is calculated excluding the effect of the 2015 non- recurring income. 18% 2016 novo nordisk

View entire presentation